Medications
Biohaven Receives FDA May Proceed Letter For Phase 3 Clinical Trial Of BHV-3241 For Multiple System Atrophy
01/29/2019
NEW HAVEN, Conn., Jan. 23, 2019 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven") announced today the U.S. Food and Drug Administration (FDA) has notified the
Read More
